Related references
Note: Only part of the references are listed.Assessment of CYP2C19 genetic polymorphisms in a korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles
K. -A. Kim et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2010)
A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism
N. G. Hunfeld et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Rabeprazole A Review of its Use in the Management of Gastric Acid-Related Diseases in Adults
Claudine M. Baldwin et al.
DRUGS (2009)
Effect of CYP2C19*2 and*17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians
Nicole G. Hunfeld et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele;: a pharmacokinetic study in healthy volunteers
R. Michael Baldwin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Proton pump inhibitors: an update of their clinical use and pharmacokinetics
Shaojun Shi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: An open, randomized crossover trial
Zhao-Shen Li et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers
V. Norris et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects
Steve Warrington et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Persistence and adherence to proton pump inhibitors in daily clinical practice
EM Van Soest et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SC Sim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19:: Evidence from clinical and pharmacokinetic data
M Schwab et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Comparison of an increased dosage regimen of rabcprazolc versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P4502C19 genotypes
M Sugimoto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects
YM Hu et al.
ACTA PHARMACOLOGICA SINICA (2005)
Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression
T Shimatani et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders
M Robinson
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects
SB Des Varannes et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status
M Sugimoto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms
K Röhss et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors
D Pantoflickova et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers
CH Wilder-Smith et al.
DIGESTION (2003)
The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers
WJ Tamminga et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH
N Shirai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations
S Yamada et al.
JOURNAL OF GASTROENTEROLOGY (2001)
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes
Y Horai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole
T Andersson et al.
CLINICAL PHARMACOKINETICS (2001)
CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole
K Adachi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2000)
Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects
WP Geus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2000)
The proton-pump inhibitors: Similarities and differences
J Horn
CLINICAL THERAPEUTICS (2000)
Share Paper
